Providence Portland Medical Center

Institution (Healthcare)

Homepage Wikipedia ROR

Also Known As

Providence Portland Medical Center · Acronym: PPMC

2.8K

Publications

295.5K

Citations

281

Authors

586

Concepts

About

Providence Portland Medical Center is a healthcare institution in Portland, United States known for medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	34	239	24.4K
2	Engineering	11	22	652
3	Education	4	4	166
4	Arts	2	4	55
5	Business	2	8	248

Providence Portland Medical Center

2.8K

Publications

295.5K

Citations

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, The Lancet HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular Carcinoma	2017	4.2K
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, New England Journal of Medicine	2018	2.5K
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, Cell Microenvironment EvolutionTumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint Inhibitor	2017	2.5K
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study Franck Pagès, Bernhard Mlecnik, Florence Marliot, The Lancet Prognostic BiomarkersOncologyInternational ValidationMedicineImmunology	2018	2K
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America Brad Spellberg, R. Guidos, David N. Gilbert, Clinical Infectious Diseases Antibiotic ResistanceUnited StatesInfectious Diseases SocietyAntibiotic-resistant InfectionsDrug Resistance	2007	1.6K
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, The Lancet Oncology Gastrointestinal OncologyMedicineHepatobiliary TumorBiliary CancerGastroenterology	2020	1.5K
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi, Julien Mazières, David Planchard, The Lancet Oncology Checkmate 063Single-arm TrialMedicineImmunologyImmune Checkpoint Inhibitor	2015	1.4K
The Oregon Experiment — Effects of Medicaid on Clinical Outcomes Katherine Baicker, Sarah Taubman, Heidi Allen, New England Journal of Medicine	2013	1.1K
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Dung T. Le, Tae Won Kim, Eric Van Cutsem, Journal of Clinical Oncology	2019	975

Page 1